Place Raymond Blyckaerts, 13
B-1050 Brussels, Belgium

Opening hours:
Mon to Thu: 10h - 12h30 and 13h30 - 17h
Fri: 10h - 12h30 and 13h30 - 16h

Google maps

Find us on
Google Maps
To subscribe to our newsletter, please click here. If you would like to become an EATG member, please fill in the form here. You can also subscribe to our RSS feed by clicking here.
You can also follow us on one of these media :

Gilead applies for PrEP approval in Canada

Gilead Sciences has applied for approval of Truvada (tenofovir/emtricitabine) as pre-exposure prophylaxis (PrEP) in Canada, reports. If the country’s health ministry, Health Canada, approves the new indication for the antiretroviral (ARV), Canada would follow the United States to become only the second nation in the world to give the green light to this new...


Source Source: POZ

The Trans-Pacific Partnership Agreement and implications for access to essential medicines

The TPP Agreement includes 12 Asia-Pacific countries (United States, Canada, Mexico, Peru, Chile, Japan, Vietnam, Malaysia, Singapore, Brunei, Australia, and New Zealand) with a collective trading power amounting to 40% of the global gross domestic product. To read the article in full, click here .


Source Source: JAMA

White House is pressed to help widen access to hepatitis C drugs via Medicaid

WASHINGTON — Federal and state Medicaid officials should widen access to prescription drugs that could cure tens of thousands of people with hepatitis C, including medications that can cost up to $1,000 a pill, health care experts have told the White House. The experts, from the Public Health Service and President Obama’s Advisory Council on H.I.V./AIDS , said...


Where do I fit in? PrEP and transgender men

When I read results from clinical trials about PrEP—or other HIV prevention tools or strategies for that matter—I’m often left wondering: Where do I fit in? There aren’t guidelines about Truvada-based PrEP use for transgender men who have sex with men because there haven’t been any studies specifically looking at how the drug works in our bodies. In fact,...


Source Source: BETA Blog

Anti-hep B treatment drives changes in liver transplantation

Hepatitis B virus is third leading indication for transplant at one institution Powerful anti-hepatitis B virus (HBV) drugs can potentially decrease the recurrence of the HBV in liver transplant patients, and even lower the number of transplants that result from complications related to HBV, according to a retrospective study. After a median follow-up of 82 months,...


Source Source: MedPage Today